| Preview | Issue Date | Title | Author(s) |
| 2012 | A framework for quantifying net benefits of alternative prognostic models | Rapsomaniki, E.; White, I.; Wood, A.; Thompson, S.; Tipping, R.; Ford, C.; Simpson, L.; Folsom, A.; Chambless, L.; Panagiotakos, D.; Pitsavos, C.; Chrysohoou, C.; Stefanadis, C.; Knuiman, M.; Whincup, P.; Wannamethee, S.; Morris, R.; Kiechl, S.; Willeit, J.; Oberhollenzer, F.; et al. |
| 2014 | Apoptosis, proliferation and inflammation are improved after treatment with the new selective glp-2 receptor agonist, elsiglutide, in a rat model of irinotecan-induced mucositis | Mayo, B.; Stringer, A.; Bateman, E.; Bowen, J.; Wignall, A.; Wozniak, B.; White, I.; Pietra, C.; Cantoreggi, S.; Keefe, D.; COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress (2 Dec 2014 - 4 Dec 2014 : Melbourne, Vic.) |
| 2014 | Assessing risk prediction models using individual participant data from multiple studies | Pennells, L.; Kaptoge, S.; White, I.; Thompson, S.; Wood, A.; Tipping, R.; Folsom, A.; Couper, D.; Ballantyne, C.; Coresh, J.; Goya Wannamethee, S.; Morris, R.; Kiechl, S.; Willeit, J.; Willeit, P.; Schett, G.; Ebrahim, S.; Lawlor, D.; Yarnell, J.; Gallacher, J.; et al. |
| 2012 | C-reactive protein, fibrinogen, and cardiovascular disease prediction | Kaptoge, S.; Di Angelantonio, E.; Pennells, L.; Wood, A.; White, I.; Gao, P.; Walker, M.; Thompson, A.; Sarwar, N.; Caslake, M.; Butterworth, A.; Amouyel, P.; Assmann, G.; Bakker, S.; Barr, E.; Barrett-Connor, E.; Benjamin, E.; Björkelund, C.; Brenner, H.; Brunner, E.; et al. |
| 2015 | Covariate-adjusted measures of discrimination for survival data | White, I.; Rapsomaniki, E.; Wannamethee, S.; Morris, R.; Willeit, J.; Willeit, P.; Santer, P.; Kiechl, S.; Wald, N.; Ebrahim, S.; Lawlor, D.; Gallacher, J.; Yarnell, J.; Ben-Shlomo, Y.; Casiglia, E.; Tikhonoff, V.; Sutherland, S.; Nietert, P.; Keil, J.; Bachman, D.; et al. |
| 2016 | Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms | Wardill, H.; Gibson, R.; Van Sebille, Y.; Secombe, K.; Coller, J.; White, I.; Manavis, J.; Hutchinson, M.; Staikopoulos, V.; Logan, R.; Bowen, J. |
| 2015 | Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study | Bowen, J.; White, I.; Smith, L.; Tsykin, A.; Kristaly, K.; Thompson, S.; Karapetis, C.; Tan, H.; Game, P.; Irvine, T.; Hussey, D.; Watson, D.; Keefe, D. |
| 2015 | Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study | Coller, J.; White, I.; Logan, R.; Tuke, J.; Richards, A.; Mead, K.; Karapetis, C.; Bowen, J. |
| 2014 | The new selective glp-2 receptor agonist, elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat | Mayo, B.; Bateman, E.; Stringer, A.; Plews, E.; Wignall, A.; Wozniak, B.; White, I.; Pietra, C.; Cantoreggi, S.; Keefe, D.; COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress (2 Dec 2014 - 4 Dec 2014 : Melbourne, Vic.) |
| 2018 | What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis | Vale, C.; Fisher, D.; White, I.; Carpenter, J.; Burdett, S.; Clarke, N.; Fizazi, K.; Gravis, G.; James, N.; Mason, M.; Parmar, M.; Rydzewska, L.; Sweeney, C.; Spears, M.; Sydes, M.; Tierney, J. |
